MetalloBio's mission is fundamentally to change the nature of antibiotics and the treatment of infections.
The need for radically different agents in the fight against untreatable infections has never been greater. Given the typical attrition rate of drug development programmes it is clear that there are too few AMR innovations currently in development. The urgency of the situation is reflected in the emergence of government-level initiatives to incentivise innovators and to ensure that effective antibacterials are valued appropriately; and recent deals demonstrate that certain major pharmaceutical companies are seeking assets in this space.
Following from the company’s business model, MetalloBio is a value growth investment proposition. As an innovative antimicrobials company we expect to commercialise a lead series of antibiotic drug candidates once they have reached Phase 2 clinical trials, most likely through licensing. However, we remain open to other routes to realising the value of the company, for example through M&A.
Funding History
Since its inception in early 2021, MetalloBio has raised ~ $2 million in non-dilutive funding including multiple Innovate UK grants, and funding from INCATE.
In 2024, the company raised its first equity investment round and is able to offer a compelling opportunity to invest in an increasingly de-risked proposition which has the potential to grow significantly in value.